Assessing cognitive function in patients treated with immune checkpoint inhibitors: A feasibility study

Stefania Cuzzubbo; Catherine Belin; Kader Chouahnia; Barouyr Baroudjian; Boris Duchemann; Ciprian Barlog; Giulia Coarelli; Renata Ursu; Elodie Poirier; Celeste Lebbe; Antoine F Carpentier

doi:10.1002/pon.4725

Assessing cognitive function in patients treated with immune checkpoint inhibitors: A feasibility study

Psychooncology. 2018 Jul;27(7):1861-1864. doi: 10.1002/pon.4725. Epub 2018 Apr 19.

Authors

Stefania Cuzzubbo^{1

2}, Catherine Belin^{1

2}, Kader Chouahnia³, Barouyr Baroudjian⁴, Boris Duchemann³, Ciprian Barlog⁵, Giulia Coarelli⁵, Renata Ursu^{1

2}, Elodie Poirier⁶, Celeste Lebbe⁴, Antoine F Carpentier^{1

2}

Affiliations

¹ Service de Neurologie, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
² Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
³ Service d'Oncologie Médicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.
⁴ APHP Dermatology and CIC Departments, INSERM U976, Université Paris Diderot, Sorbonne Paris Cité, Hôpital Saint Louis, Paris, France.
⁵ Service de Neurologie, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.
⁶ Service de Dermatologie, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.

PMID: 29624771
DOI: 10.1002/pon.4725

No abstract available

Keywords: anti-CTLA4; anti-PD1; cancer; chemobrain; chemotherapy; cognition; immune checkpoint inhibitor; memory impairment; neurotoxicity; oncology.